India pacer Jasprit Bumrah has risen to second in the latest ICC Twenty20 rankings while skipper Virat Kohli has retained the top spot in the batsmen's list.
There is no change in the top three of the all-rounders' table which is headed by Shakib Al Hasan of Bangladesh.
Pakistan's ICC Champions Trophy-winning side's member Imad Wasim has become the number-one ranked T20 bowler after South Africa's Imran Tahir lost ground following the conclusion of the series against England.
In the latest rankings for T20 bowlers, which was updated a day after England beat South Africa 2-1, Tahir has slipped two places after he managed only one wicket in two matches.
His drop to third means Imad has surged to the top for the first time in his career, with Bumrah rising to second.
In the batting table, Kohli, Aaron Finch of Australia and Kane Williamson of New Zealand have retained the top three positions.
However, AB de Villiers and Jason Roy are the biggest movers following the just-concluded series.
De Villiers, who was the leading run-getter in the series with 146 runs, has returned to the top 20 in 20th position after rising 12 places, while Roy's series aggregate of 103 runs has helped him achieve a career-high 25th position after jumping 26 places.
In the team rankings, England has moved into outright second position. It had started the series level with Pakistan on 121 points, but has now moved to 123 points to trail number-one ranked New Zealand by two points.
In contrast, South Africa has dropped one point to join Australia on 110 points. However, it is ranked ahead of Australia by a fraction of a point, and occupies the sixth position.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.